Teknova Expects Q2 Total Revenue Of $9.4M - $9.6M, Est $9.327M

7/9/24 5:06:47 PM ET

Biotechnology: In Vitro & In Vivo Diagnostic Substances

Health Care

Get the next $TKNO alert in real time by email

Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million, down 17% to 18% when compared to second quarter 2023. However, when adjusted to remove an unusually large Clinical Solutions order, second quarter 2024 revenue increased by 7% to 9%.

Teknova continues to anticipate Free Cash Outflow of less than $18 million for 2024 – with $3.0 to $3.4 million of total cash used in the second quarter of 2024.

Teknova expects to report its complete financial results for the second quarter of 2024 on August 13th, 2024, following the close of market.

Get the next $TKNO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TKNO

Date	Price Target	Rating	Analyst
3/12/2024		Buy → Neutral	BTIG Research
7/20/2021		Overweight	Stephens
7/20/2021	$27.00	Overweight	Stephens & Co.
7/20/2021		Outperform	Cowen & Co.
7/20/2021	$26.00	Buy	BTIG

More analyst ratings

$TKNO
Financials

Live finance-specific insights

Teknova Reports Third Quarter 2024 Financial Results
Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2024. "Our year-on-year double-digit revenue growth in the third quarter gives us confidence that we have put Teknova on track f
11/7/24 4:01:00 PM ET
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you woul
10/24/24 4:01:00 PM ET
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Teknova Reports Second Quarter 2024 Financial Results
Second quarter 2024 total revenue was $9.6 million, up 3% sequentiallyRaised $15.4 million of equity capital in July 2024Launched two new offerings: Express-TekSM Production and RUO+ manufacturing gradeCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2024. "We delivered solid results across the board in the first half of 2024," said Stephen Guns
8/13/24 4:01:00 PM ET
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Teknova Reports Third Quarter 2024 Financial Results
Third quarter 2024 total revenue was $9.6 million, up 17% over the same quarter prior yearCompany lowers 2024 total free cash outflow outlook to less than $16 millionCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2024. "Our year-on-year double-digit revenue growth in the third quarter gives us confidence that we have put Teknova on track f
11/7/24 4:01:00 PM ET
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024
HOLLISTER, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, following the close of market. Teknova will host a webcast and conference call on Thursday, November 7, 2024, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you woul
10/24/24 4:01:00 PM ET
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Teknova Reports Second Quarter 2024 Financial Results
Second quarter 2024 total revenue was $9.6 million, up 3% sequentiallyRaised $15.4 million of equity capital in July 2024Launched two new offerings: Express-TekSM Production and RUO+ manufacturing gradeCompany reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2024. "We delivered solid results across the board in the first half of 2024," said Stephen Guns
8/13/24 4:01:00 PM ET
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC
7/24/24 1:26:11 PM ET
$ALGM
$ALKS
$ALLR
$ATCH
Semiconductors
Technology
Biotechnology: Pharmaceutical Preparations
Health Care
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
7/22/24 1:28:23 PM ET
$APLD
$ATPC
$AVAH
$CGC
Finance: Consumer Services
Finance
Medical/Nursing Services
Health Care
Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) fell sharply during Wednesday's session after the company announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. ASLAN Pharmaceuticals shares dipped 38.7% to $0.68 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Aptevo Therapeutics Inc. (NASDAQ:APVO) shares climbed 84% to $0.6073 after surging around 10% on Tuesday. Aptevo Therapeutics recently announced closing of $2.75 million offering. Shimmick Corporation (NASDAQ:SHIM) shares climbed 49% to $3.0173 after the company received a $27.6 million subcontract for the Sunol Valley Water Trea
7/17/24 1:28:51 PM ET
$ADTX
$ADVM
$AEHR
$ALLR
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Electrical Products

Teknova Expects Q2 Total Revenue Of $9.4M - $9.6M, Est $9.327M

Chat with this insight

Recent Analyst Ratings for $TKNO

$TKNO Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Large owner Telegraph Hill Partners Iv, L.P. bought $14,999,999 worth of shares (12,096,773 units at $1.24) (SEC Form 4)

Chief Financial Officer Lowell Matthew bought $49,999 worth of shares (40,322 units at $1.24), increasing direct ownership by 46% to 128,376 units (SEC Form 4)

President and CEO Gunstream Stephen bought $100,000 worth of shares (80,645 units at $1.24), increasing direct ownership by 50% to 243,497 units (SEC Form 4)

$TKNO Financials

Live finance-specific insights

Teknova Reports Third Quarter 2024 Financial Results

Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024

Teknova Reports Second Quarter 2024 Financial Results

$TKNO SEC Filings

SEC Form 10-Q filed by Alpha Teknova Inc.

Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form 424B3 filed by Alpha Teknova Inc.

$TKNO Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$TKNO Large Ownership Changes

This live feed shows all institutional transactions in real time.

$TKNO Press Releases

Fastest customizable press release news feed in the world

Large owner Telegraph Hill Partners Iv, L.P. bought $14,999,999 worth of shares (12,096,773 units at $1.24) (SEC Form 4)

Chief Financial Officer Lowell Matthew bought $49,999 worth of shares (40,322 units at $1.24), increasing direct ownership by 46% to 128,376 units (SEC Form 4)

President and CEO Gunstream Stephen bought $100,000 worth of shares (80,645 units at $1.24), increasing direct ownership by 50% to 243,497 units (SEC Form 4)

SEC Form SC 13D filed by Alpha Teknova Inc.

SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

SEC Form SC 13G/A filed by Alpha Teknova Inc. (Amendment)

Teknova Reports Third Quarter 2024 Financial Results

Teknova to Report Third Quarter 2024 Financial Results on November 7, 2024

Teknova Reports Second Quarter 2024 Financial Results

$TKNO Leadership Updates

Live Leadership Updates

Teknova Announces New Board Member, Martha J. Demski

$TKNO Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Alpha Teknova downgraded by BTIG Research

Stephens initiated coverage on Alpha Teknova

Stephens & Co. initiated coverage on Alpha Teknova with a new price target

$TKNO Market Insights

Live Market Insights

Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Recent Analyst Ratings for
$TKNO

$TKNO
Insider Trading

$TKNO
Financials

$TKNO
SEC Filings

$TKNO
Insider Purchases

$TKNO
Large Ownership Changes

$TKNO
Press Releases

$TKNO
Leadership Updates

$TKNO
Analyst Ratings

$TKNO
Market Insights